GO
Loading...

AstraZeneca PLC

More

  • Early movers: AOL, GM, TWTR, P, COST, GOOG & more Thursday, 6 Feb 2014 | 7:40 AM ET
    Traders work the floor of the New York Stock Exchange on the evening of January 23, 2014 in New York City.

    Some of the names on the move ahead of the open.

  • *Alcatel-Lucent surges 11.5 percent after results. LONDON, Feb 6- European equities bounced back from oversold technical levels on Thursday after a sharp two-week drop, with reassuring earnings from major companies Alcatel-Lucent and AkzoNobel boosting their shares.

  • *Q4 sales $6.84 bln vs consensus $6.88 bln. *Q4 core earnings per share $1.23 vs consensus $1.16. LONDON, Feb 6- AstraZeneca expects earnings to keep falling in 2014 as generic competition to its popular heartburn and ulcer drug Nexium takes a big bite out of U.S. profits from late May.

  • MUMBAI/ LONDON, Feb 6- Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent, sources with direct knowledge of the matter said.

  • European shares bounce back; Alcatel surges Thursday, 6 Feb 2014 | 3:17 AM ET

    PARIS, Feb 6- European shares rose in early trade on Thursday, bouncing back from a sharp two-week selloff, with telecom gear maker Alcatel-Lucent surging 7.4 percent after posting reassuring results. The market's rebound could be limited, however, ahead of a European Central Bank meeting later in the day.

  • *Q4 core earnings per share $1.23 vs $1.16. LONDON, Feb 6- AstraZeneca expects earnings to continue to fall in 2014 as generic competition to its popular heartburn and ulcer drug Nexium takes a big bite out of U.S. profits from May. Shares in AstraZeneca fell 1 percent in early trading.

  • LONDON, Feb 6- AstraZeneca expects earnings to continue to fall in 2014 as generic competition to its popular heartburn and ulcer drug Nexium takes a big bite out of U.S. profits from May. Sales in the fourth quarter of 2013 fell 6 percent to $6.84 billion, generating "core" earnings, which exclude certain items, down 28 percent at $1.23 a share.

  • Markets could drift as traders await jobs report Wednesday, 5 Feb 2014 | 8:58 PM ET

    Markets are in wait-and-see mode ahead of Friday's jobs report, but there are a few events Thursday that could sway the market's direction.

  • *Pfizer to discuss favorable data with FDA. Feb 3- Pfizer Inc's experimental breast cancer drug significantly delayed progression of symptoms in a mid-stage trial, meeting the study's primary goal and keeping Pfizer in the forefront of a race for a new standard of care for the disease.

  • Squawking Henny Youngman, supermodels, selloff Thursday, 30 Jan 2014 | 11:46 AM ET
    Henny Youngman in 1992

    Talking Squawk, the "Squawk Box" blog, provides tidbits, insights and sarcastic reflections on the WEEK THAT WAS and the WEEK TO COME.

  • BASEL, Jan 29- Novartis is looking at options, such as joint ventures, for three smaller businesses to bring them in line with its world-leading pharmaceutical operations, it said on Wednesday, in a review due to be completed by the end of summer.

  • Jan 28- Amgen Inc on Tuesday reported a quarterly profit that beat Wall Street forecasts, as it gained full control of its blockbuster rheumatoid arthritis drug Enbrel and saw solid growth in sales of newer products.

  • Jan 28- Amgen Inc on Tuesday reported a forecast-beating quarterly profit, as the profit-sharing agreement on its blockbuster rheumatoid arthritis drug Enbrel became more favorable and on lower taxes.

  • Jan 24- Bristol-Myers Squibb Co on Friday reported stronger-than-expected quarterly results, but its shares fell because of investors' jitters about the pace at which the company is developing a promising new combination of cancer drugs.

  • *Knocks back Teva's Nerventra and Novartis' serelaxin. LONDON, Jan 24- Europe's drugs regulator gave its backing on Friday for marketing approval to be granted for Bayer's pulmonary hypertension drug Adempas and for GlaxoSmithKline's diabetes medicine Eperzan.

  • UPDATE 1-GSK diabetes drug set for European approval Friday, 24 Jan 2014 | 8:25 AM ET

    LONDON, Jan 24- GlaxoSmithKline said on Friday European regulators had given the green light to its once-weekly diabetes drug albiglutide, which it is marketing as Eperzan. Albiglutide belongs to the same class of injectable GLP-1 drugs as Victoza from Novo Nordisk, as well as Byetta and Bydureon from Bristol-Myers Squibb and AstraZeneca.

  • UPDATE 1-Bristol-Myers beats sales, profit forecasts Friday, 24 Jan 2014 | 8:04 AM ET

    Jan 24- Bristol-Myers Squibb Co's quarterly sales and earnings beat Wall Street expectations, helped by cost cuts and growing sales of its treatments for cancer, blood clots and diabetes. The company on Friday said it earned $726 million, or 44 cents per share, in the fourth quarter.

  • WASHINGTON/ MUMBAI, Jan 23- Indian drugmaker Ranbaxy Laboratories Ltd faces long delays and high costs in launching big-selling generic drugs in the United States after products from a fourth plant were banned from entering its main market due to manufacturing violations.

  • Jan 21- Amarin Corp Plc's shares fell more than 26 percent after U.S. health regulators rejected a preset testing process that was critical to the company seeking broader use of its blood fat-lowering drug. Analysts are skeptical of Amarin's ability to run a profitable business without the new indication of its only approved drug, Vascepa.

  • *Analysts had forecast annual sales of $407 mln by 2017. ZURICH, Jan 21- An experimental Roche drug designed to treat the "negative symptoms" of schizophrenia failed to meet its main goal in two late-stage studies, dealing a blow to the Swiss drugmaker's research hopes in the risky area of brain science.

Most Popular Video

Thursday, 17 Apr 2014 | 1:03 PM ET

Dissecting the current market action amid geopolitical concerns, with Kenny Polcari, O'Neil Securities, and CNBC's Dominic Chu.

Thursday, 17 Apr 2014 | 12:06 PM ET

Discussing the case for stocks, with Ed Yardeni, president and chief investment strategist of Yardeni Research. He thinks the market had an "internal correction."

Thursday, 17 Apr 2014 | 1:00 PM ET

Secretary of State John Kerry comments after a meeting in Geneva with Russian Foreign Minister Sergey Lavrov and representatives of the EU and Ukraine.